表紙:老眼:パイプライン製品の分析
市場調査レポート
商品コード
410994

老眼:パイプライン製品の分析

Presbyopia (Ophthalmology) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 78 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
老眼:パイプライン製品の分析
出版日: 2021年12月30日
発行: Global Markets Direct
ページ情報: 英文 78 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

老眼は、近くにある対象物に素早く焦点を合わせる能力がゆっくり失われていく目の状態です。老眼は、加齢とともに起こります。症候は、頭痛、眼精疲労、細かい字が読みにくい、疲労などがあります。危険因子として、貧血症、糖尿病、循環器系疾患、遠視、多発性硬化症、重症筋無力症、眼外傷などが挙げられます。

当レポートでは、老眼の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階に関する情報などを提供しています。

イントロダクション

  • 調査範囲

老眼 概要

治療薬の開発

  • パイプライン製品;概要

企業で開発中の治療薬

パイプライン製品の概況

  • 治験段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Allergan Plc
  • Encore Vision Inc
  • Orasis Pharmaceuticals Ltd
  • Presbyopia Therapies LLC
  • ViewPoint Therapeutics Inc

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (aceclidine + tropicamide)
  • (oxymetazoline hydrochloride + pilocarpine hydrochloride)
  • EV-06
  • lanosterol
  • oxymetazoline hydrochloride
  • PresbiDrops
  • VP-1001

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development for Presbyopia, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Presbyopia - Pipeline by AbbVie Inc, 2021
  • Presbyopia - Pipeline by Cellix Bio Pvt Ltd, 2021
  • Presbyopia - Pipeline by Eyenovia Inc, 2021
  • Presbyopia - Pipeline by Glaukos Corp, 2021
  • Presbyopia - Pipeline by Intratus Inc, 2021
  • Presbyopia - Pipeline by Kedalion Therapeutics Inc, 2021
  • Presbyopia - Pipeline by Kubota Vision Inc, 2021
  • Presbyopia - Pipeline by Lenz Therapeutics LLC, 2021
  • Presbyopia - Pipeline by Novartis AG, 2021
  • Presbyopia - Pipeline by Ocuphire Pharma Inc, 2021
  • Presbyopia - Pipeline by Orasis Pharmaceuticals Ltd, 2021
  • Presbyopia - Pipeline by Plex Pharmaceuticals Inc, 2021
  • Presbyopia - Pipeline by Reven Holdings Inc, 2021
  • Presbyopia - Pipeline by Santen Pharmaceutical Co Ltd, 2021
  • Presbyopia - Pipeline by ViewPoint Therapeutics Inc, 2021
  • Presbyopia - Pipeline by Visus Therapeutics Inc, 2021
  • Presbyopia - Pipeline by Vyluma Inc, 2021
  • Presbyopia - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Presbyopia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13216IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Drugs In Development, 2021, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.

Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 3, 4 and 2 respectively.

Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Presbyopia - Overview
  • Presbyopia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Presbyopia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Presbyopia - Companies Involved in Therapeutics Development
  • Presbyopia - Drug Profiles
  • Presbyopia - Dormant Projects
  • Presbyopia - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer